Efpeglenatide, a novel long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), shows promise for the treatment of type 2 diabetes mellitus (T2DM) and obesity. The gene discussed is GCG; the disease is type 2 diabetes mellitus.